During the day, representatives from the company will speak about the company’s core business of scalp cooling, reimbursement in the U. S. and the merger with Dignitana. There will be a strong focus on the company’s latest side effect management work related to chemotherapy-induced peripheral neuropathy (CIPN), including a product demonstration.

CEO Richard Paxman OBE and Dr. Aishwarya Bandla, Regional R&D Manager at Paxman, who has led the development of a wearable limb cryocompression device to prevent CIPN, will be presenting at the event.

The event will be held at Carnegie’s premises in Stockholm, Sweden and a live webcast will be available for those who cannot attend in person.

Location: Regeringsgatan 56, 111 56 Stockholm.

Date & Time: 26 November 2025, 13:00-17:00

Agenda

12:15 - 13:00 - Lunch

13:00 - 13:15 – Introduction

13:15 – 13:45 – Richard Paxman OBE: regulatory pathways and go-to-market strategy for Paxman’s cryocompression device to prevent CIPN

13:45 - 14:45 – Dr. Aishwarya Bandla: the patient burden of CIPN, cryocompression trial data, and live demonstration of the device.

(15 min Q&A and break)

15:00-15:45 – Reimbursement landscape and the IBBM business model

(15 min Q&A and break)

16:00-16:45 – The impact of the Dignitana merger, followed by Q&A

16:45–17:00 – Closing remarks: summary of the day and the future of Paxman

Registration for physical or online attendance to the Capital Market Day can be done via this link.

For inquiries regarding event-related questions, kindly send an email to anna.olsson@carnegie.se.